Amoxicillin is Better Than Augmentin for Acute Bacterial Tonsillitis
For routine acute bacterial tonsillitis (Group A Streptococcal pharyngitis), amoxicillin alone is the preferred first-line treatment over Augmentin (amoxicillin-clavulanate). Augmentin should be reserved for specific situations: chronic GAS carriers requiring eradication or recurrent/persistent infections with specific risk factors.
Primary Treatment Recommendation
The IDSA guidelines 1 do not recommend amoxicillin-clavulanate as first-line therapy for acute streptococcal pharyngitis. The guidelines only mention Augmentin in Table 5 specifically for chronic carriers of Group A Streptococci requiring eradication (strong recommendation, moderate quality evidence), not for acute infection treatment.
When to Use Amoxicillin (First-Line):
- All routine cases of acute bacterial tonsillitis/pharyngitis
- Proven or suspected Group A Streptococcal infection
- Standard dosing for treatment duration per guidelines
When Augmentin May Be Considered:
Chronic Carrier Eradication 1:
- Community outbreak of acute rheumatic fever or invasive GAS
- Outbreak in closed/semi-closed community
- Family/personal history of acute rheumatic fever
- Family with excessive anxiety about GAS infections
- When tonsillectomy is being considered only because of carriage
- Dosing: 40 mg amoxicillin/kg/day in 3 doses × 10 days (max 2000 mg/day)
Recurrent/Persistent Acute Otitis Media (not tonsillitis) 2:
- FDA-approved indication for pediatric patients with specific risk factors:
- Antibiotic exposure within preceding 3 months, AND
- Age ≤2 years OR daycare attendance
- Due to S. pneumoniae (penicillin MIC ≤2 mcg/mL), H. influenzae, or M. catarrhalis
Evidence Analysis
Supporting Narrow-Spectrum Therapy:
Recent high-quality evidence strongly supports amoxicillin over Augmentin:
2026 JAMA study 3: In 234,608 propensity-matched adults with acute sinusitis, amoxicillin showed no difference in treatment failure compared to amoxicillin-clavulanate (3.1% vs 3.0%; RR 0.96), but Augmentin had higher risk of secondary infections including yeast infections (RR 1.40) and C. difficile (RR 2.14)
2026 retrospective study 4: Among 38,810 patients with comorbidities and acute rhinosinusitis, treatment failure rates were equivalent between amoxicillin and Augmentin, with chronic/subacute sinusitis more frequent with Augmentin
Pediatric Tonsillitis Data:
2013 Japanese study 5: 3-day Augmentin showed 98.1% clinical response vs 92.9% for 10-day amoxicillin in pediatric pharyngolaryngitis, but GAS eradication was lower with Augmentin (65.4% vs 85.4%). Importantly, even with lower eradication, no acute glomerulonephritis occurred in either group
2024 comparative study 6: Co-amoxiclav, cefpodoxime, and levofloxacin showed comparable clinical and bacteriological cure rates in acute bacterial tonsillitis
Clinical Algorithm
Step 1: Confirm acute bacterial tonsillitis (not viral pharyngitis)
- Positive rapid strep test or culture
- Clinical features: tonsillar exudates, fever, tender anterior cervical nodes, absence of cough
Step 2: Determine if patient is acute infection vs chronic carrier
- Acute infection: Symptomatic with rising antibody titers → Use amoxicillin
- Chronic carrier: Asymptomatic colonization with intercurrent viral illness → Usually no treatment needed
Step 3: If chronic carrier requires eradication (see specific situations above) → Consider Augmentin or other regimens from Table 5 1
Step 4: For routine acute tonsillitis → Prescribe amoxicillin (not Augmentin)
Key Pitfalls to Avoid
Don't use Augmentin for routine acute streptococcal pharyngitis - This promotes unnecessary broad-spectrum coverage, increases adverse events (especially secondary infections), and contradicts stewardship principles 7
Don't confuse carrier state with acute infection - Chronic carriers with positive throat cultures during viral illnesses don't need antibiotics at all, let alone Augmentin
Don't assume "stronger is better" - The clavulanate component targets β-lactamase-producing organisms, which is irrelevant for Group A Streptococcus (GAS doesn't produce β-lactamase)
Recognize that lower bacteriological eradication doesn't equal treatment failure - The 5 study showed that even with lower GAS eradication rates, clinical outcomes and prevention of complications (glomerulonephritis) were equivalent
Antimicrobial Stewardship Context
The WHO AWaRe classification places amoxicillin-clavulanate in the "Access" group 7, but this doesn't mean it should replace narrower-spectrum amoxicillin for infections where the narrower agent is effective. The principle is to use the narrowest effective spectrum to minimize collateral damage to the microbiome and reduce resistance selection pressure.